TREATMENT OF DISEASES RELATED WITH GENE DLG BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT OF DLG GENE Russian patent published in 2017 - IPC C12N15/113 A61K48/00 A61K31/7088 C12N15/63 

FIELD: biochemistry.

SUBSTANCE: invention relates to biochemistry. Described an oligonucleotide with length approximately from 15 to 30 nucleotides, containing at least one modification, note here that said at least one modification selected from: at least one modified sugar residue; at least one modified internucleotide linkage; at least one modified nucleotide; and their combinations. Note here that said oligonucleotide is hybridized with natural antisense transcript of gene Discs large homolog 1 (DLG1) and has the sequence, at least at 80 % identical to reverse component of section of the sequence SEQ ID NO: 2, or has the sequence, at least at 80 % identical to the section of the sequence SEQ ID NO: 1. Invention also relates to use of said antisense oligonucleotide for treatment diseases and disorders associated with expression of gene DLG1.

EFFECT: invention extends the range of agents for treatment diseases and disorders associated with DLG gene expression.

33 cl, 2 dwg, 1 tbl, 3 ex